Australian Drug Maker Close To Cure For Common Cold

Australian drug maker Biota announced Wednesday the success of its antiviral compound, named Vapendavir, bringing it closer to a cure for the common cold.

Tested in 300 asthmatic patients infected with the cold-causing human rhinovirus, the clinical trial showed that cold symptoms eased quickly and the duration of the infection was shortened considerably, according to a report in the Herald Sun.

Patients given a placebo experienced the worst cold symptoms at 2.5 days, whereas those dosed with Vapendavir began rapid recovery after just 1.7 days.

Read the full article here.